Published on : Apr 05, 2017
Albany, New York, April 05, 2017: The report takes into account various aspects of the global coagulants market, including its dynamic, competitive scenario, and region-wise outlook to offer an immaculate understanding to the readers.
As per the findings of the report, the global anticoagulant market is poised to post a CAGR of more than 7% between 2017 and 2021. The burgeoning demand for novel oral anticoagulants (NOACs) is one of the leading factor augmenting the global market. The acceptance of NOACs is high, owing to their quicker action, better safety, and higher efficiency as compared to traditional therapies such as warfarin. The increasing incidence of coagulation disorders worldwide also has a significant impact on the growth of the market. Moreover, the growing number of people undergoing hip and knee surgeries is providing a fillip to the global market for anticoagulants.
On the other hand, the high costs of NOACs are a major impediment to the growth of the market. Furthermore, the inadequate availability of antidotes for NOACs is hampering the growth prospects of the market. However, an upswing in the number of patient assistance programs is anticipated to augur well for the growth of the market in the near future.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=1027767
On the basis of route of administration, the global anticoagulant market is segmented into oral and injectable. The oral segment will continue to enjoy the leading share in the revenue pie until 2021. The cost-effectiveness and painless nature of this treatment are encouraging patients to uptake anticoagulant drugs. Based on drug class, the market is divided into factor Xa inhibitors, heparin, DTIs, and vitamin K antagonists. The factor Xa inhibitors segment will continue to account for the lion’s share in the market. The approval of drugs such as edoxaban, rivaroxaban, and apixaban has provided a significant momentum to the growth of the segment.
The key regions analyzed in the report are Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific. Americas will continue to dominate the market until 2021. The growth of the region can be attributed to the introduction of NOACs. The strong demand for vitamin K antagonists is also driving the growth of the region.
The strong competition between regional players and international companies in terms of product pricing has rendered the global anticoagulant market highly competitive. The market is likely to witness tremendous growth owing to the increasing usage of NOACs and growing number of surgeries worldwide, which in turn will attract new players to venture into the market. Established players are estimated to capitalize immense potential offered by emerging markets in order to maximize their revenue generation.
The leading companies in the market are Johnson & Johnson, Bayer HealthCare, Bristol-Myers, Squibb, Boehringer Ingelheim, Daiichi Sankyo, and Sanofi. Some other prominent companies operating in the market are Eli Lilly, AstraZeneca, LEO Pharma, Keryx Biopharmaceuticals, and Pfizer.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on email@example.com